The knowns and unknowns of long COVID-19: from mechanisms to therapeutical approaches

Front Immunol. 2024 Mar 4:15:1344086. doi: 10.3389/fimmu.2024.1344086. eCollection 2024.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has been defined as the greatest global health and socioeconomic crisis of modern times. While most people recover after being infected with the virus, a significant proportion of them continue to experience health issues weeks, months and even years after acute infection with SARS-CoV-2. This persistence of clinical symptoms in infected individuals for at least three months after the onset of the disease or the emergence of new symptoms lasting more than two months, without any other explanation and alternative diagnosis have been named long COVID, long-haul COVID, post-COVID-19 conditions, chronic COVID, or post-acute sequelae of SARS-CoV-2 (PASC). Long COVID has been characterized as a constellation of symptoms and disorders that vary widely in their manifestations. Further, the mechanisms underlying long COVID are not fully understood, which hamper efficient treatment options. This review describes predictors and the most common symptoms related to long COVID's effects on the central and peripheral nervous system and other organs and tissues. Furthermore, the transcriptional markers, molecular signaling pathways and risk factors for long COVID, such as sex, age, pre-existing condition, hospitalization during acute phase of COVID-19, vaccination, and lifestyle are presented. Finally, recommendations for patient rehabilitation and disease management, as well as alternative therapeutical approaches to long COVID sequelae are discussed. Understanding the complexity of this disease, its symptoms across multiple organ systems and overlapping pathologies and its possible mechanisms are paramount in developing diagnostic tools and treatments.

Keywords: Inflammatory markers; PASC; SARS-CoV-2; brain fog; vascular injury.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • COVID-19*
  • Disease Management
  • Disease Progression
  • Humans
  • Post-Acute COVID-19 Syndrome
  • SARS-CoV-2

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by a grant of the Ministry of Research, Innovation and Digitization, under the Romania’s National Recovery and Resilience Plan funded by EU Next Generation EU program, project “Artificial intelligence-powered personalized health and genomics libraries for the analysis of long-term effects in COVID-19 patients (AI-PHGL-COVID)” number 760073/23.05.2023, code 285/30.11.2022, within Pillar III, Component C9, Investment 8 and by a grant of the Ministry of Research, Innovation and Digitization, CNCS, UEFISCDI, project number PN-III-Pl-1.1-PD-2021-0273, within PNCDI III.